Home › Companies › aTyr Pharma, Inc. › 2024-2025
At aTyr Pharma, Inc.'s shareholder meeting held May 1, 2025, in the 2024-2025 proxy season, 55 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 237 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers; — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: aTyr Pharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 6, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and aTyr Pharma, Inc.’s Form 8-K, filed May 6, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 1, 2025: 5 items on aTyr Pharma, Inc.’s Form 8-K, filed May 6, 2025: 2 elected · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore aTyr Pharma, Inc. in the interactive database Compare manager voting policies
These tallies are aTyr Pharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Paul Schimmel, Ph.D. | 56,592,548 | -- | -- | 255,242 | 12,438,762 | 99.5% | Elected | — |
| Elect Director: Sara L. Zaknoen, M.D. | 48,990,895 | -- | -- | 7,856,895 | 12,438,762 | 86% | Elected | — |
| 2. Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 | 68,905,147 | 175,747 | 205,658 | -- | -- | 99.7% | Not verified | — |
| 3. Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement | 55,237,719 | 1,353,536 | 256,535 | -- | 12,438,762 | 98% | Not verified | — |
| 4. Approval of an amendment to the 2015 Stock Plan | 56,252,712 | 358,711 | 236,367 | -- | 12,438,762 | 99.3% | Not verified | — |
Source: aTyr Pharma, Inc., Form 8-K, filed with the SEC on May 6, 2025 — read the filing on EDGAR.
Each item below shows how the 55 asset managers that disclosed a aTyr Pharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors, as nominated by the Company's Board of Directors (the "Board of Directors"), to hold office until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified: Paul Schimmel, Ph.D.
aTyr Pharma, Inc.’s own tally for this item (“Elect Director: Paul Schimmel, Ph.D.”): 56,592,548 for, 255,242 withheld, per its Form 8-K filed May 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 25,306,877 for, 134,943 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 14,641,300 | 0 | 0 | 0 | For |
| Fidelity | 6,743,373 | 0 | 0 | 0 | For |
| Vanguard | 3,843,075 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 126,258 | Withhold |
| Charles Schwab | 39,689 | 0 | 0 | 0 | For |
| Equitable | 13,977 | 0 | 0 | 0 | For |
| Victory Capital | 9,673 | 0 | 0 | 0 | For |
| BlackRock | 8,195 | 0 | 0 | 0 | For |
| American Century | 5,785 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 0 | 0 | 4,540 | Withhold |
| Jackson National | 0 | 0 | 0 | 4,145 | Withhold |
| John Hancock | 1,358 | 0 | 0 | 0 | For |
| State Street | 452 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors, as nominated by the Company's Board of Directors (the "Board of Directors"), to hold office until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified: Sara L. Zaknoen, M.D.
aTyr Pharma, Inc.’s own tally for this item (“Elect Director: Sara L. Zaknoen, M.D.”): 48,990,895 for, 7,856,895 withheld, per its Form 8-K filed May 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 25,290,061 for, 151,759 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 14,641,300 | 0 | 0 | 0 | For |
| Fidelity | 6,743,373 | 0 | 0 | 0 | For |
| Vanguard | 3,843,075 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 126,258 | Withhold |
| Charles Schwab | 39,689 | 0 | 0 | 0 | For |
| Equitable | 13,977 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 9,673 | Withhold |
| BlackRock | 8,195 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 5,785 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 4,540 | Withhold |
| Jackson National | 0 | 0 | 0 | 4,145 | Withhold |
| John Hancock | 0 | 0 | 0 | 1,358 | Withhold |
| State Street | 452 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended; and
aTyr Pharma, Inc.’s own tally for this item (“4. Approval of an amendment to the 2015 Stock Plan”): 56,252,712 for, 358,711 against, per its Form 8-K filed May 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 25,665,074 for, 5,785 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 14,641,300 | 0 | 0 | 0 | For |
| Fidelity | 6,743,373 | 0 | 0 | 0 | For |
| Vanguard | 3,843,075 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 229,039 | 0 | 0 | 0 | For |
| Dimensional | 126,258 | 0 | 0 | 0 | For |
| Charles Schwab | 39,689 | 0 | 0 | 0 | For |
| Equitable | 13,977 | 0 | 0 | 0 | For |
| Victory Capital | 9,673 | 0 | 0 | 0 | For |
| BlackRock | 8,195 | 0 | 0 | 0 | For |
| American Century | 0 | 5,785 | 0 | 0 | Against |
| Prudential/PGIM | 4,540 | 0 | 0 | 0 | For |
| Jackson National | 4,145 | 0 | 0 | 0 | For |
| John Hancock | 1,358 | 0 | 0 | 0 | For |
| State Street | 452 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers;
aTyr Pharma, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 55,237,719 for, 1,353,536 against, per its Form 8-K filed May 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 14,641,300 | 0 | 0 | 0 | For |
| Fidelity | 6,743,373 | 0 | 0 | 0 | For |
| Vanguard | 3,843,075 | 0 | 0 | 0 | For |
| Dimensional | 126,258 | 0 | 0 | 0 | For |
| Charles Schwab | 39,689 | 0 | 0 | 0 | For |
| Equitable | 13,977 | 0 | 0 | 0 | For |
| Victory Capital | 9,673 | 0 | 0 | 0 | For |
| BlackRock | 8,195 | 0 | 0 | 0 | For |
| American Century | 5,785 | 0 | 0 | 0 | For |
| Prudential/PGIM | 4,540 | 0 | 0 | 0 | For |
| Jackson National | 4,145 | 0 | 0 | 0 | For |
| John Hancock | 1,358 | 0 | 0 | 0 | For |
| State Street | 452 | 0 | 0 | 0 | For |
Fund voting reports, all 13 managers: 25,441,820 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 14,641,300 | 0 | 0 | 0 | For |
| Fidelity | 10,880,149 | 0 | 0 | 0 | For |
| Point72 | 4,639,698 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 3,320,000 | 0 | 0 | 0 | For |
| Tikvah Management LLC | 2,460,833 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,208,790 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 0 | 1,178,441 | 0 | 0 | Against |
| BlackRock | 1,155,345 | 0 | 0 | 0 | For |
| Logos Global Management LP | 800,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 740,366 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 640,000 | 0 | 0 | 0 | For |
| Ally Bridge Group (NY) LLC | 582,230 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 493,413 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 371,544 | 0 | 0 | 0 | For |
| Renaissance | 346,436 | 0 | 0 | 0 | For |
| Knott David M Jr | 308,133 | 0 | 0 | 0 | For |
| Citadel | 265,919 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 229,039 | 0 | 0 | 0 | For |
| State Street | 135,130 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 125,035 | 0 | 0 | 0 | For |
| Northern Trust | 82,881 | 0 | 0 | 0 | For |
| Wellington | 82,831 | 0 | 0 | 0 | For |
| Goldman Sachs | 74,215 | 0 | 0 | 0 | For |
| Dimensional | 49,516 | 0 | 0 | 0 | For |
| D.A. DAVIDSON & CO. | 40,200 | 0 | 0 | 0 | For |
Institutional-manager reports, all 52 managers: 43,984,101 for, 1,180,506 against. Showing the 25 largest; every one is in the interactive database (link above).
99.7% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;
aTyr Pharma, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025”): 68,905,147 for, 175,747 against, per its Form 8-K filed May 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 25,441,820 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 14,641,300 | 0 | 0 | 0 | For |
| Fidelity | 6,743,373 | 0 | 0 | 0 | For |
| Vanguard | 3,843,075 | 0 | 0 | 0 | For |
| Dimensional | 126,258 | 0 | 0 | 0 | For |
| Charles Schwab | 39,689 | 0 | 0 | 0 | For |
| Equitable | 13,977 | 0 | 0 | 0 | For |
| Victory Capital | 9,673 | 0 | 0 | 0 | For |
| BlackRock | 8,195 | 0 | 0 | 0 | For |
| American Century | 5,785 | 0 | 0 | 0 | For |
| Prudential/PGIM | 4,540 | 0 | 0 | 0 | For |
| Jackson National | 4,145 | 0 | 0 | 0 | For |
| John Hancock | 1,358 | 0 | 0 | 0 | For |
| State Street | 452 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 88,858,612 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Federated Hermes | 16.48% |
| 2 | Fidelity | 7.59% |
| 3 | Vanguard | 4.32% |
| 4 | Dimensional | 0.14% |
| 5 | Charles Schwab | 0.04% |
| 6 | Equitable | 0.02% |
| 7 | Victory Capital | 0.01% |
| 8 | BlackRock | <0.01% |
| 9 | American Century | <0.01% |
| 10 | Prudential/PGIM | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Federated Hermes | 16.48% |
| 2 | Fidelity | 12.24% |
| 3 | Point72 | 5.22% |
| 4 | Octagon Capital Advisors LP | 3.74% |
| 5 | Tikvah Management LLC | 2.77% |
| 6 | Woodline Partners LP | 1.36% |
| 7 | Alyeska Investment Group, L.P. | 1.33% |
| 8 | BlackRock | 1.30% |
| 9 | Logos Global Management LP | 0.90% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.83% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| 1001 Liberty Avenue | 16.51% | DEF14A |
| FMR (Fidelity) | 14.51% | 13F |
| Federated Hermes, Inc. | 11.87% | 13G |
| Summer Street | 9.89% | DEF14A |
| FMR LLC | 6.68% | 13G |
| Cummings Point Road | 5.67% | DEF14A |
| Vanguard Group | 4.51% | 13F |
| Point72 Asset Management, L.P. | 3.20% | 13G |
| Point72 | 3.20% | 13F |
| Millennium Management | 1.80% | 13F |
Percentages above are of 88,858,612 shares outstanding, as reported by aTyr Pharma, Inc. on its Form 10-K dated March 7, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from aTyr Pharma, Inc.’s 10-K dated March 7, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
aTyr Pharma, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “aTyr Pharma (ATYR) 2025 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/atyr-pharma-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.